Avexegen Therapeutics Receives a $2.94M NIH Grant to Advance Treatment for Inflammatory Bowel Disease

SAN FRANCISCO, Feb. 15, 2021 -- (Healthcare Sales & Marketing Network) -- Avexegen Therapeutics Inc. today announced that it has received a Phase 2 award of $2.94 million under the National Institutes of Health's Small Business Innovation Research Program... Biopharmaceuticals, Gastroenterology Avexegen Therapeutics, inflammatory bowel disease, Crohn's Disease
Source: HSMN NewsFeed - Category: Pharmaceuticals Source Type: news